Pharma consulting(ファーマコンサルティング)では、経験豊富なコンサルタントが弊社のデータベース群をフル活用し、かつ、外部の情報ソースも利用してお客様のニーズに合わせた個別の市場調査・分析を行います。
コンサルティングで下記のニーズにお応えします：
Pharma consultingご利用のメリットを1分間の動画にまとめました。ぜひご覧下さい。
インフォーマセミナー講演動画
Pharma consultingのシニアディレクター・Timothy Pangが、Pharma consultingサービスのケーススタディを交えて講演を行いました。
1. Bringing data alive: Consulting Case Studies(2018年2月／東京)
2. New horizons, fresh opportunities: Tech, Big Data, and the next pharma wave(2017年11月／東京)
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consulting: 医療用医薬品の...
Catch up on any missed COVID-19 24 hour webinar sessions
Topic Cardiovascular Coronavirus
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus clinical-trials
Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Topic Coronavirus FDA Drug Review
Biomedtracker: 開発中医薬品をFDA承認確率で評価
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Biomedtracker: 開発中医薬品をFDA承認確率で評価
In preparation for the webinar, download your free infographic, a snapshot view of M&A’s biggest deals and major players and what their activities indicate for the year ahead.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...
Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.
Topic Coronavirus
Biomedtracker: 開発中医薬品をFDA承認確率で評価
In this infographic, we provide insight into key trials that are expecting developments in the approval process.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.
Topic fda
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...
The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.
Biomedtracker: 開発中医薬品をFDA承認確率で評価
Biomedtracker boils down all the important mergers and acquisitions activities in Q1.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...
What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.
Biomedtracker: 開発中医薬品をFDA承認確率で評価
What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.
Topic Drug approval Drug review FDA
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.
UK
Timothy specializes in
+24 year(s) experience
UK
Duncan specializes in
+20 year(s) experience
お問い合わせ先
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
